Gw Pharmaceuticals Plc Stock Current Valuation
Valuation analysis of GW Pharmaceuticals Plc helps investors to measure GW Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
GW Pharmaceuticals Plc Company Current Valuation Analysis
GW Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current GW Pharmaceuticals Current Valuation | 6.42 B |
Most of GW Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GW Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, GW Pharmaceuticals Plc has a Current Valuation of 6.42 B. This is 55.3% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all United States stocks is 61.38% higher than that of the company.
GWPH Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GW Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GW Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GW Pharmaceuticals by comparing valuation metrics of similar companies.GW Pharmaceuticals is currently under evaluation in current valuation category among related companies.
GWPH Fundamentals
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 | |||
| Profit Margin | (11.03) % | |||
| Operating Margin | (9.82) % | |||
| Current Valuation | 6.42 B | |||
| Shares Outstanding | 31.54 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.35 % | |||
| Number Of Shares Shorted | 693.73 K | |||
| Price To Earning | 126.70 X | |||
| Price To Book | 9.24 X | |||
| Price To Sales | 12.92 X | |||
| Revenue | 527.2 M | |||
| Gross Profit | 489.67 M | |||
| EBITDA | (39.01 M) | |||
| Net Income | (58.13 M) | |||
| Cash And Equivalents | 486.75 M | |||
| Cash Per Share | 15.53 X | |||
| Total Debt | 43.64 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 4.57 X | |||
| Book Value Per Share | 23.70 X | |||
| Cash Flow From Operations | (27.39 M) | |||
| Short Ratio | 1.15 X | |||
| Earnings Per Share | (1.86) X | |||
| Price To Earnings To Growth | 3.61 X | |||
| Number Of Employees | 1.16 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 6.81 B | |||
| Total Asset | 453.18 M | |||
| Retained Earnings | (813.7 M) | |||
| Working Capital | 369.57 M | |||
| Current Asset | 404.52 M | |||
| Current Liabilities | 34.95 M | |||
| Z Score | 93.2 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GW Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GW Pharmaceuticals' short interest history, or implied volatility extrapolated from GW Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |